Esaote launched its MyLab Eight ultrasound platform at the Radiological Society of North America annual meeting, which occurred in Chicago from November 27 to December 2. The company’s ultrasound technology includes the new eMPowered Engine, which leverages high-density, single crystal transducers to enable deeper image capture within the body—all of which results in high-fidelity images, even with patients who are difficult to scan.
The platform’s new WideView visualization technology provides sharp diagnostic image clarity, in addition to enhanced spatial and contrast resolution. XFlow and HD CRM—Esaote’s high-frequency imaging and advanced hemodynamic evaluation tools—work in conjunction with a comprehensive portfolio of probes to cater to departments including cardiovascular, obstetrics and gynecology, interventional, radiology, and surgery.
The MyLab Eight ultrasound platform can focus on the prevention of work-related musculoskeletal disorders. It includes Appleprobe transducers and MyLabRemote, an interface app that allows the system to be controlled by smartphone or tablet. To cater to clinical and research environments, the technology’s advanced tools include the Qealto shear wave quantitative elastography, virtual navigator real-time fusion imaging, radiofrequency-based quality intima media thickness, quality arterial stiffness quantification, and contrast-tuned imaging ultrasound, among others.
According to Glenn Davis, president and general manager of Esaote North America, “The release of the MyLab Eight is very important to Esaote North America in continuing to expand our ultrasound portfolio for our customers. As a leader in interventional ultrasound and fusion imaging, we are excited to see the positive impact this will provide to our customer and their.
For more information about this platform, visit Esaote.
